GAMMA Investing LLC Acquires 25,785 Shares of Pfizer Inc. (NYSE:PFE)

GAMMA Investing LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 69.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 63,131 shares of the biopharmaceutical company's stock after purchasing an additional 25,785 shares during the period. GAMMA Investing LLC's holdings in Pfizer were worth $1,600,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Pfizer by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock valued at $13,756,738,000 after purchasing an additional 2,285,276 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after purchasing an additional 25,315,159 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Pfizer by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock valued at $3,190,131,000 after purchasing an additional 2,923,537 shares during the last quarter. Norges Bank bought a new position in shares of Pfizer during the 4th quarter valued at $2,328,986,000. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after purchasing an additional 5,350,381 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on PFE. UBS Group increased their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Stock Performance

Shares of PFE opened at $24.20 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a 50-day simple moving average of $23.46 and a two-hundred day simple moving average of $24.84. The firm has a market capitalization of $137.56 billion, a PE ratio of 17.53, a price-to-earnings-growth ratio of 0.88 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the business posted $0.82 earnings per share. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.11%. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.